Intra- and peritumoral radiomics features based on multicenter automatic breast volume scanner for noninvasive and preoperative prediction of HER2 status in breast cancer: a model ensemble research

被引:5
|
作者
Wang, Hui [1 ,2 ]
Chen, Wei [3 ]
Jiang, Shanshan [4 ]
Li, Ting [3 ]
Chen, Fei [1 ]
Lei, Junqiang [5 ]
Li, Ruixia [1 ]
Xi, Lili [6 ]
Guo, Shunlin [5 ]
机构
[1] Lanzhou Univ, Dept Ultrasound, Hosp 1, Lanzhou, Gansu, Peoples R China
[2] Lanzhou Univ, Clin Med Coll 1, Lanzhou, Gansu, Peoples R China
[3] Ningxia Hui National Autonomous Reg Peoples Hosp, Dept Ultrasound, Yinchuan, Ningxia, Peoples R China
[4] Dept Adv Tech Support, Clin & Tech Support, Philips Healthcare, Xian, Shanxi, Peoples R China
[5] Lanzhou Univ, Dept Radiol, Hosp 1, Lanzhou, Gansu, Peoples R China
[6] Lanzhou Univ, Dept Endocrinol, Hosp 1, Lanzhou, Gansu, Peoples R China
关键词
ULTRASOUND; PATHOLOGY; SURVIVAL; HEAD;
D O I
10.1038/s41598-024-55838-4
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The aim to investigate the predictive efficacy of automatic breast volume scanner (ABVS), clinical and serological features alone or in combination at model level for predicting HER2 status. The model weighted combination method was developed to identify HER2 status compared with single data source model method and feature combination method. 271 patients with invasive breast cancer were included in the retrospective study, of which 174 patients in our center were randomized into the training and validation sets, and 97 patients in the external center were as the test set. Radiomics features extracted from the ABVS-based tumor, peritumoral 3 mm region, and peritumoral 5 mm region and clinical features were used to construct the four types of the optimal single data source models, Tumor, R3mm, R5mm, and Clinical model, respectively. Then, the model weighted combination and feature combination methods were performed to optimize the combination models. The proposed weighted combination models in predicting HER2 status achieved better performance both in validation set and test set. For the validation set, the single data source model, the feature combination model, and the weighted combination model achieved the highest area under the curve (AUC) of 0.803 (95% confidence interval [CI] 0.660-947), 0.739 (CI 0.556,0.921), and 0.826 (95% CI 0.689,0.962), respectively; with the sensitivity and specificity were 100%, 62.5%; 81.8%, 66.7%; 90.9%,75.0%; respectively. For the test set, the single data source model, the feature combination model, and the weighted combination model attained the best AUC of 0.695 (95% CI 0.583, 0.807), 0.668 (95% CI 0.555,0.782), and 0.700 (95% CI 0.590,0.811), respectively; with the sensitivity and specificity were 86.1%, 41.9%; 61.1%, 71.0%; 86.1%, 41.9%; respectively. The model weighted combination was a better method to construct a combination model. The optimized weighted combination models composed of ABVS-based intratumoral and peritumoral radiomics features and clinical features may be potential biomarkers for the noninvasive and preoperative prediction of HER2 status in breast cancer.
引用
收藏
页数:14
相关论文
共 37 条
  • [31] Noninvasive identification of HER2-low-positive status by MRI-based deep learning radiomics predicts the disease-free survival of patients with breast cancer
    Guo, Yuan
    Xie, Xiaotong
    Tang, Wenjie
    Chen, Siyi
    Wang, Mingyu
    Fan, Yaheng
    Lin, Chuxuan
    Hu, Wenke
    Yang, Jing
    Xiang, Jialin
    Jiang, Kuiming
    Wei, Xinhua
    Huang, Bingsheng
    Jiang, Xinqing
    EUROPEAN RADIOLOGY, 2024, 34 (02) : 899 - 913
  • [32] Noninvasive identification of HER2-low-positive status by MRI-based deep learning radiomics predicts the disease-free survival of patients with breast cancer
    Yuan Guo
    Xiaotong Xie
    Wenjie Tang
    Siyi Chen
    Mingyu Wang
    Yaheng Fan
    Chuxuan Lin
    Wenke Hu
    Jing Yang
    Jialin Xiang
    Kuiming Jiang
    Xinhua Wei
    Bingsheng Huang
    Xinqing Jiang
    European Radiology, 2024, 34 : 899 - 913
  • [33] Predictive value of 18F-FDG PET/CT radiomic fusion features combined with XGBoost model for HER2 expression status in breast cancer
    陈旖文
    ChinaMedicalAbstracts(InternalMedicine), 2023, 40 (02) : 65 - 65
  • [34] IMPLEMENTATION OF A DATA MINING MODEL WITHIN A MONITORING WEB-BASED TOOL TO ASSESS HER2 BREAST CANCER STATUS USING THE HER-FRANCE REAL WORLD DATABASE
    Vauleon, T.
    Pau, D.
    Dupin, P.
    Magrez, D.
    Martin, J.
    Bellocq, J.
    VALUE IN HEALTH, 2017, 20 (09) : A748 - A748
  • [35] Prognostic impact of HER2 overexpression/amplification in women with pT1a NO MO breast cancer with known screening status: Results from a multicenter population-based cancer registry study
    Musolino, A.
    Michiara, M.
    Boggiani, D.
    Sikokis, A.
    Rimanti, A.
    Pellegrino, B.
    Silini, E. M.
    Campanini, N.
    Barbieri, E.
    Sgargi, P.
    Falcini, F.
    Pinto, C.
    CANCER RESEARCH, 2016, 76
  • [36] Topoisomerase IIα gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer
    Orlando, Laura
    Del Curto, Barbara
    Gandini, Sara
    Ghisini, Raffaella
    Pietri, Elisabetta
    Torrisi, Rosalba
    Balduzzi, Alessandra
    Cardillo, Anna
    Dellapasqua, Silvia
    Veronesi, Paolo
    Viale, Giuseppe
    Goldhirsch, Aron
    Colleoni, Marco
    BREAST, 2008, 17 (05): : 506 - 511
  • [37] Prognostic impact of HER2 overexpression/amplification in women with pT1a N0 M0 breast cancer with known screening status: First results from a multicenter population-based cancer registry study.
    Musolino, Antonino
    Michiara, Maria
    Boggiani, Daniela
    Sikokis, Angelica
    Rimanti, Anita
    Pellegrino, Benedetta
    Martella, Eugenia
    Bozzani, Francesco
    Sgargi, Paolo
    Panebianco, Michele
    Bisagni, Giancarlo
    Falcini, Fabio
    Pinto, Carmine
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)